Posted by Michael Wonder on 19 Nov 2025
Eylea HD (aflibercept) injection 8 mg approved by FDA for the treatment of macular oedema following retinal vein occlusion and for monthly dosing across approved indications
19 November 2025 - Regeneron Pharmaceuticals today announced that the US FDA has approved Eylea HD (aflibercept) injection 8 mg for the treatment of patients with macular oedema following retinal vein occlusion with up to every 8 week dosing after an initial monthly dosing period.
The FDA also approved an every 4 week (monthly) dosing option for some patients who may benefit from resuming this dosing schedule across approved indications: wet age-related macular degeneration, diabetic macular oedema, diabetic retinopathy and retinal vein occlusion.
